

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name- Picodya - * Website- <https://picodya.com/> *

CEO name- Tzvika Barkai *

Select a CATEGORY: Medical Devices *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

- **Frontiers in Biochip and Bio-Devices; Advancing Technological Systems with Cutting-Edge Biology**

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Founded in 2018, Picodya aims to make comprehensive, near-patient diagnostics more accessible across both clinical and research environments worldwide.

- **Core Technology** What is the technology, its uniqueness, and its value proposition?

Advanced film-based multilayer, high-density microfluidic consumables enable complex assay workflow automation “inside the box”

- **Product Profile/Pipeline** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

The E-Matrix™ ecosystem is tailored for the Research and CLIA-LDT markets, serving academic institutions, pharmaceutical companies, CROs, and Biotech firms. This innovative platform replaces complex manual liquid handling steps in multiplex bead-based immunoassay workflows with microfluidic-based microtiter plates that automate 96 simultaneous reactions.

Picodya's B-Matrix™ platform is a versatile clinical diagnostic solution optimized for point-of-care settings. It performs rapid, high-precision hybrid molecular and

immunoassay testing from a variety of sample types. Designed for clinics, hospitals, and pharmacies.

- Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

The E-Matrix soft-launched in late 2025, with immediate revenues in the research market. The B-Matrix post FDA approval in 2-3 years will create the major revenue build-up.

- What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Complete development of the E-Matrix and organizational growth